# HiberGene Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hibergene-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Dublin, Ireland
- Website: www.hibergene.com
- Total disclosed funding: $2.3M
- Latest round: Series A (Feb 2, 2015)
- Investors on record: 2

## About

HiberGene Diagnostics Limited focuses on developing and manufacturing advanced diagnostic tests for infectious diseases, utilizing innovative proprietary technology to enhance patient outcomes.HiberGene Diagnostics Limited, founded in 2009 in Dublin, Ireland, specializes in diagnostic solutions for infectious diseases. The company has executed a total of three deals, with its latest funding round occurring on March 31, 2017, raising EUR 4.95 million from Med Captain and other investors. Peter Kidney is the founder, while David Corr serves as the CEO.HiberGene Diagnostics specializes in the development and manufacture of advanced diagnostic tests for human infectious diseases, primarily utilizing its proprietary LAMP technology. The company’s flagship products include rapid diagnostic tests for meningitis, specifically targeting the two prevalent forms—Meningococcus and Pneumococcal Meningitis. These tests provide highly sensitive and timely detection of the disease, facilitating prompt treatment in clinical settings. HiberGene's products cater to hospitals and healthcare providers across Europe, North America, and parts of Asia, enhancing healthcare by ensuring rapid and accurate diagnoses of critical conditions.HiberGene Diagnostics operates within the USD 57 billion in-vitro diagnostics market, generating revenue through the sales of its innovative diagnostic products. The company primarily engages in B2B transactions, selling its tests through partnerships with healthcare institutions and distributors. Revenue is derived from direct sales to hospitals and laboratories, allowing for efficient testing of infectious diseases. HiberGene aims to expand its market presence via strategic commercial agreements, including licensing and distribution deals.With the recent funding of EUR 4.95 million raised on March 31, 2017, HiberGene Diagnostics plans to enhance its product line by developing new diagnostic tests aimed at other infectious diseases. The company is working towards expanding its reach into additional markets in Asia and North America by late 2023, which will facilitate greater accessibility to its diagnostic tools and improve patient care in these regions.

## Funding rounds

- Series A, Feb 2, 2015, $2.3M — Kernel Capital, Enterprise Ireland

## Investors

- Kernel Capital (https://capitalatlas.ai/funds/kernel-capital) — Series A
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series A